Canada-based commercialisation firm Mars Innovation has secured an $800,000 commitment from pharmaceutical firm Pfizer to establish a translational research fund.
The Mars Innovation – Pfizer Translational Research Fund will focus on technologies in life sciences, including therapeutics, diagnostic and treatment tools, manufacturing and research-enabling products.
The fund will particularly seek to identify projects related to rare diseases, cancer, vaccines, inflammation, immunology and cardiovascular disease. It will be managed by Mars Innovation.
Raphael Hofstein, president and CEO of Mars Innovation, said: “Mars Innovation is thrilled to continue our long-standing collaboration with Pfizer; a partnership with a focus on translating the highly qualified research coming from our 15 member institutions.
“Pfizer’s contribution to Mars Innovation’s efforts in accelerating the pace of commercialisation of transformational research is invaluable. It is also opportune that our strategic partnership with Pfizer Canada exemplifies the stated goal of federal and provincial governments to continue to support commercialisation of home-grown excellent science.”
– This article originally appeared on our sister site, Global University Venturing.